Outcome of Infants with Therapeutic Hypothermia after Perinatal Asphyxia and Early-Onset Sepsis.


Journal

Neonatology
ISSN: 1661-7819
Titre abrégé: Neonatology
Pays: Switzerland
ID NLM: 101286577

Informations de publication

Date de publication:
2019
Historique:
received: 05 05 2018
accepted: 27 08 2018
pubmed: 13 11 2018
medline: 18 12 2019
entrez: 13 11 2018
Statut: ppublish

Résumé

Animal models suggest that neuroprotective effects of therapeutic hypothermia (TH) after perinatal asphyxia are reduced in infants with early-onset sepsis. To assess the outcome of infants with perinatal asphyxia, neonatal encephalopathy, and TH in the presence of early-onset sepsis. In a retrospective cohort of 1,084 infants with perinatal asphyxia and TH, the outcome of 42 infants (gestational age 36.1-42.6 weeks and birth weight 2,280-5,240 g) with proven sepsis (n = 14) and probable sepsis (n = 28) was analyzed. Death, cerebral palsy, or a delayed development at 2 years was considered an adverse outcome. Sepsis was caused mostly by group B streptococci (n = 17), other Gram-positive bacteria (n = 5), and Candida albicans (n = 1). Of the 42 infants, 9 (21.4%) died, and 5 (11.9%) showed impairments on follow-up. The outcome is comparable to the previously reported outcome of infants with TH without early-onset sepsis. A good outcome was reported in the majority of infants with perinatal asphyxia, TH, and early-onset sepsis. Cooling should not be withheld from these infants.

Sections du résumé

BACKGROUND
Animal models suggest that neuroprotective effects of therapeutic hypothermia (TH) after perinatal asphyxia are reduced in infants with early-onset sepsis.
OBJECTIVES
To assess the outcome of infants with perinatal asphyxia, neonatal encephalopathy, and TH in the presence of early-onset sepsis.
METHODS
In a retrospective cohort of 1,084 infants with perinatal asphyxia and TH, the outcome of 42 infants (gestational age 36.1-42.6 weeks and birth weight 2,280-5,240 g) with proven sepsis (n = 14) and probable sepsis (n = 28) was analyzed. Death, cerebral palsy, or a delayed development at 2 years was considered an adverse outcome.
RESULTS
Sepsis was caused mostly by group B streptococci (n = 17), other Gram-positive bacteria (n = 5), and Candida albicans (n = 1). Of the 42 infants, 9 (21.4%) died, and 5 (11.9%) showed impairments on follow-up. The outcome is comparable to the previously reported outcome of infants with TH without early-onset sepsis.
CONCLUSION
A good outcome was reported in the majority of infants with perinatal asphyxia, TH, and early-onset sepsis. Cooling should not be withheld from these infants.

Identifiants

pubmed: 30419568
pii: 000493358
doi: 10.1159/000493358
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-133

Informations de copyright

© 2018 The Author(s) Published by S. Karger AG, Basel.

Auteurs

Mariam Hakobyan (M)

Department of Neonatology, Wilhelmina Children's Hospital, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands.

Koen P Dijkman (KP)

Department of Neonatology, Máxima Medical Centre, Veldhoven, The Netherlands.

Sabrina Laroche (S)

Department of Neonatology, University Hospital, Antwerp, Belgium.

Gunnar Naulaers (G)

Department of Neonatology, University Hospital, Leuven, Belgium.

Monique Rijken (M)

Department of Neonatology, Leiden University Medical Center, Leiden, The Netherlands.

Katerina Steiner (K)

Department of Neonatology, Radboud University Medical Center, Radboud Institute for Health Science, Amalia Children's Hospital, Nijmegen, The Netherlands.

Henrica L M van Straaten (HLM)

Department of Neonatology, Isala Clinics, Zwolle, The Netherlands.

Renate M C Swarte (RMC)

Department of Neonatology, Erasmus Medical Center Sophia, Rotterdam, The Netherlands.

Hendrik J Ter Horst (HJ)

Department of Neonatology, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands.

Alexandra Zecic (A)

Department of Neonatology, University Hospital, Gent, Belgium.

Inge A Zonnenberg (IA)

Department of Neonatology, VU University Medical Center, Amsterdam, The Netherlands.

Floris Groenendaal (F)

Department of Neonatology, Wilhelmina Children's Hospital, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands, F.Groenendaal@umcutrecht.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH